IGC Pharma, Inc. IGC
0.20 USD -0.01 (-4.11%)
At closeNov 10, 2026, 5:06 PM EST
0.19 0.00 -2.50%
After hours · Nov 10, 5:06 PM ET
0.1907 Day range 0.2049
0.08 52-week range 0.40
- YTD
- -30.00%
- 1 year
- -48.42%
News
benzinga.com IGC Pharma Receives Patent From Canadian Intellectual Property Office Covering Composition Of IGC-AD1 Therapy For Agitation In Alzheimer IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI) enabled healthcare
benzinga.com Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket Celestica jumps 16.4% after beating Q3 FY26 estimates and raising guidance; 22nd Century leads premarket gainers at 69.8%.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap…
accessnewswire.com IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment POTOMAC, MD / ACCESS Newswire / October 13, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and…
defenseworld.net IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0% IGC Pharma, Inc. (NYSEAMERICAN:IGC - Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totaling…
benzinga.com 'DEA Judge Pauses Marijuana Rescheduling Hearing As Opponents Highlight Government Report Detailing ‘Gaps’ In Federal Processes'- Marijuana Moment https://www.marijuanamoment.net/dea-judge-pauses-marijuana-rescheduling-hearing-as-opponents-highlight-government-report-detailing-gaps-in-federal-processes/
accessnewswire.com IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 POTOMAC, MD / ACCESS Newswire / September 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced it has completed enrollment in its CALMA Phase 2 trial evaluating…
benzinga.com Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6 Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.5 to $6.
benzinga.com IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of $(0.02) per…
accessnewswire.com IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC), a…
accessnewswire.com IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease,…
accessnewswire.com IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign POTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease,…
accessnewswire.com IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development…
benzinga.com IGC Pharma Says CEO Ram Mukunda And Principal Financial Officer Claudia Grimaldi Purchase Aggregate Of 4,274,853 Shares Directly From Company At $0.27/Shr Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGCPOTOMAC, MD / ACCESS…
accessnewswire.com IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC POTOMAC, MD / ACCESS…
benzinga.com IGC Pharma Launches AI-Powered Data Harmonization Platform To Accelerate Alzheimer’s Research And Drug Discovery Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in…
accessnewswire.com IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London…
accessnewswire.com IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire /…
accessnewswire.com Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease,…
benzinga.com Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.5 Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.25 to $5.5.- benzinga.com 'White House Pushes Congress To Keep Hemp CBD Products Legal By Amending Broad Ban That's Set To Take Effect Later This Year' - Marijuana Moment https://www.marijuanamoment.net/white-house-pushes-congress-to-keep-hemp-cbd-products-legal-by-amending-broad-ban-thats-set-to-take-effect-later-this-year/
benzinga.com IGC Pharma Announces Addition Of Icahn School Of Medicine At Mount Sinai In New York As Clinical Site In Phase 2 CALMA Trial Evaluating IGC-AD1 For Agitation Associated With Alzheimer's Disease Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysisPOTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma,…
accessnewswire.com IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC…- benzinga.com "Marijuana Components Have 'Consistent' Anti-Tumor Effects In Glioblastoma And Other Cancers, Scientific Review Shows" - Marijuana Moment https://www.marijuanamoment.net/marijuana-components-have-consistent-anti-tumor-effec
accessnewswire.com IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment - Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company…
accessnewswire.com IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15,…
accessnewswire.com IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion POTOMAC, MD / ACCESS Newswire / April 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC)…- benzinga.com 'Trump Reclassifies State-Licensed Medical Marijuana As A Less-Dangerous Drug In A Historic Shift' - AP News https://apnews.com/article/medical-marijuana-rescheduling-justice-department-trump-cannabis-1d6722d3aae122b1a91f8e4b6c690268
- benzinga.com 'Trump Administration Is Expected To Move To Reclassify Marijuana As Soon As Wednesday' - Axios https://www.axios.com/2026/04/22/trump-marijuana-rule-change
- benzinga.com IGC Pharma Adds Kerwin Medical Center In Dallas, Texas As Clinical Site In Phase 2 CALMA Trial Evaluating IGC-AD1 For Agitation In Alzheimer's Disease Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation studyPOTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc.…
accessnewswire.com IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE…- benzinga.com IGC Pharma Receives Authorization In Colombia To Synthesize, Formulate, And Conduct Development Activities Involving Psilocybin At Its R&D Facility In Bogotá Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completionPOTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC…
accessnewswire.com IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion POTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC…- benzinga.com IGC Pharma Enrolls ~80% Participants In Its Phase 2 CALMA Clinical Study Of IGC-AD1 For Agitation Associated With Alzheimer's Disease IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated…
accessnewswire.com IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout POTOMAC, MD / ACCESS Newswire / April 14, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA…
accessnewswire.com Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts POTOMAC, MD / ACCESS Newswire / April 8, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company with its lead program currently in a Phase 2…- benzinga.com Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.25 Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5 to $5.25.
accessnewswire.com IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease POTOMAC, MD / ACCESS Newswire / April 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's…- benzinga.com 'Medicare CBD Pilot Will Allow Some THC in Products'- Cannabis Wire https://cannabiswire.com/newsletters/scoop-medicare-cbd-pilot-will-allow-some-thc-in-products/?free_read=1773920530418
- benzinga.com IGC Pharma Q3 EPS $(0.01) Beats $(0.02) Estimate, Sales $213.000K Miss $325.000K Estimate IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent increase over losses of $(0.02) per share…
- benzinga.com Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5 Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $4.75 to $5.
- benzinga.com 'Federal Agency Finalized Rule For CBD Medicare Coverage Pilot Program Weeks Ago, Key Hemp Stakeholder Says'- Marijuana Moment https://www.marijuanamoment.net/federal-agency-finalized-rule-for-cbd-medicare-coverage-pilot-program-weeks-ago-key-hemp-stakeholder-says/
- benzinga.com 'GOP Congressman Isn't Sure Marijuana Rescheduling Is A DOJ 'Priority,' But Remains Optimistic About Progress Under Trump' - Marijuana Moment https://www.marijuanamoment.net/gop-congressman-isnt-sure-marijuana-rescheduling-is-a-doj-priority-but-remains-optimistic-about-progress-under-trump/
- benzinga.com IGC Pharma Adds Integrative Clinical Trials Site In Brooklyn IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence ("AI") to develop innovative treatments for Alzheimer's disease, today…
- benzinga.com IGC Pharma Adds Dominion Medical Associates Clinical Research Site With Lightship's Site Network IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's…
benzinga.com 'New Hampshire House Passes Bills To Legalize Marijuana And Let Dispensaries Convert To For-Profit Status' - Marijuana Moment https://www.marijuanamoment.net/new-hampshire-house-passes-bills-to-legalize-marijuana-and-let-dispensaries-convert-to-for-profit-status/- benzinga.com 'Congressional Leaders Drop Attempt To Block Marijuana Rescheduling, While Preserving State Medical Cannabis Protections'- Marijuana Moment https://www.marijuanamoment.net/congressional-leaders-drop-attempt-to-block-marijuana-rescheduling-while-preserving-state-medical-cannabis-protections/
benzinga.com 'Florida Attorney General Asks Supreme Court To Block Marijuana Legalization Measure From Ballot' - Marijuana Moment https://www.marijuanamoment.net/florida-attorney-general-asks-supreme-court-to-block-marijuana-legalization-measure-from-ballot/- benzinga.com 'Federal Health Programs Will Cover Up To $500 Worth Of CBD For Certain Patients By April, Trump Official Dr. Oz Says'- Marijuana Moment https://www.marijuanamoment.net/federal-health-programs-will-cover-up-to-500-worth-of-cbd-for-certain-patients-by-april-trump-official-dr-oz-says/
- benzinga.com 'President Trump Directs Attorney General Pam Bondi to Finalize Marijuana Rescheduling by the End of January'- The Marijuana Herald https://themarijuanaherald.com/2025/12/president-trump-directs-attorney-general-pam-bondi-to-finalize-marijuana-rescheduling-by-the-end-of-january/